Those who receive the COVID-19 vaccine during pregnancy are less likely to be hospitalized for COVID-19; however, vaccine uptake in this population is suboptimal.

The United States government is offering another round of free COVID-19 tests, which will be available by the end of September.

Consensus recommendations have been established for pediatric mycosis fungoides, including additional clinical severity and outcome measures.

Several minimally invasive injectable modalities are safe and effective for the management of hair loss in adults with androgenetic alopecia.

Extreme temperature-related deaths are projected to increase considerably by the mid-21st century in the contiguous United States.

The aTIV vaccine provides better protection against influenza-related medical encounters than the HD-TIV vaccine in high-risk older adults.

Fructose, carbonated soft drinks, and free sugar consumption may be linked to asthma, allergic rhinitis, and food allergies in children.

Topline results were announced from a trial evaluating dapirolizumab pegol in patients with moderate to severe systemic lupus erythematosus.

Treatment with baloxavir marboxil significantly reduced the risk of onward transmission of influenza within households.

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Receiving an mRNA COVID-19 vaccine within 100 days of starting ICI therapy may improve overall survival in some patients with cancer.

Most patients with alopecia areata who had hair regrowth with baricitinib and discontinued maintenance therapy experienced a relapse of hair loss.